Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.

Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D.

Nat Genet. 2019 Mar;51(3):404-413. doi: 10.1038/s41588-018-0311-9. Epub 2019 Jan 7.

PMID:
30617256
2.

A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.

Kiddle SJ, Voyle N, Dobson RJB.

J Alzheimers Dis. 2018;64(s1):S289-S297. doi: 10.3233/JAD-179904.

3.

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.

Voyle N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ, Dobson RJ, Kiddle SJ; EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.

4.

Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins.

Voyle N, Kim M, Proitsi P, Ashton NJ, Baird AL, Bazenet C, Hye A, Westwood S, Chung R, Ward M, Rabinovici GD, Lovestone S, Breen G, Legido-Quigley C, Dobson RJ, Kiddle SJ; Alzheimer's Disease Neuroimaging Initiative.

Transl Psychiatry. 2016 Jan 26;6:e719. doi: 10.1038/tp.2015.205.

5.

A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.

Voyle N, Keohane A, Newhouse S, Lunnon K, Johnston C, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Hodges A, Kiddle S, Dobson RJ.

J Alzheimers Dis. 2016;49(3):659-69. doi: 10.3233/JAD-150440.

6.

No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease.

Chiam JT, Lunnon K, Voyle N, Proitsi P, Coppola G, Geschwind D, Nelson S, Johnston C, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Hodges A, Lovestone S, Newhouse S, Dobson RJ, Kiddle SJ, Sattlecker M.

J Alzheimers Dis. 2015;47(3):741-50. doi: 10.3233/JAD-150289.

PMID:
26401708
7.

Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology.

Voyle N, Baker D, Burnham SC, Covin A, Zhang Z, Sangurdekar DP, Tan Hehir CA, Bazenet C, Lovestone S, Kiddle S, Dobson RJ; AIBL research group.

J Alzheimers Dis. 2015;46(4):947-61. doi: 10.3233/JAD-150020.

8.

Circulating Proteomic Signatures of Chronological Age.

Menni C, Kiddle SJ, Mangino M, Viñuela A, Psatha M, Steves C, Sattlecker M, Buil A, Newhouse S, Nelson S, Williams S, Voyle N, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Spector TD, Dobson R, Valdes AM.

J Gerontol A Biol Sci Med Sci. 2015 Jul;70(7):809-16. doi: 10.1093/gerona/glu121. Epub 2014 Aug 14.

Supplemental Content

Support Center